CRXT News and Press, Clarus Therapeutics Holdings Inc. From 03/21/22

Why Investors Are Watching These 4 Trending Penny Stocks If you’re looking to get in on the action with penny stocks, it’s important to know which stocks are trending and how to find them. Utilizing methods for finding trending penny stocks can help you to have a great...

3 Hot Penny Stocks to Add to Your End of March Watchlist If you’re wondering what penny stocks to watch this month, you’re not alone. Many investors are looking for the best penny stocks to buy in order to make a high-quality watchlist with a solid chance of profitabil...

Clarus Therapeutics (NASDAQ:CRXT) began screening for the first patient in a phase 4 trial testing its oral drug Jatenzo (testosterone undecanoate) to treat hypogonadal men with chronic kidney disease (CKD). Jatenzo is an androgen approved for testosterone replacement therapy in adult ma...

JATENZO is the first and only FDA-approved oral softgel for testosterone (T) replacement therapy in adult males who have deficient T due to certain medical conditions Clarus expects to announce results from the trial in the first half of 2023 NORTHBROOK, Ill., March 16, 2022...

NORTHBROOK, Ill., March 10, 2022 (GLOBE NEWSWIRE) -- Clarus Therapeutics Holdings, Inc. (Clarus) (Nasdaq:CRXT), a pharmaceutical company dedicated to providing solutions to unmet medical needs by advancing androgen and metabolic therapies for men and women, today announced that it will pres...

JATENZO is the first and only FDA-approved oral softgel capsule for testosterone replacement therapy in adult males who have deficient testosterone due to certain medical conditions New offerings underscore Clarus’ continued commitment to providing solutions for patients ...

The FDA has accepted a New Drug Application for the oral testosterone replacement therapy ("TRT") Tlando from Antares Pharma (NYSE:ATR). The new action date is March 28. Tlando was granted tentative approval as a twice daily treatment. Previously, the FDA determined that Tlando met efficacy a...

Dr. Jumadilova most recently led clinical development programs at Insmed and Pfizer and has nearly 30 years of combined pharmaceutical and biotech experience NORTHBROOK, Ill., Jan. 18, 2022 (GLOBE NEWSWIRE) -- Clarus Therapeutics Holdings, Inc. (Clarus) (Nasdaq:CRXT), a pharmaceutic...

Gainers: Galera Therapeutics (NASDAQ:GRTX) +11%. TFF Pharmaceuticals TFFP +7%. Annexon (NASDAQ:ANNX) +6%. Clarus Therapeutics Holdings (NASDAQ:CRXT) +4%. Tyra Biosciences (NASDAQ:TYRA) +4%. Losers: CalAmp CAMP -14%. Qilian International Holding Group  (NASDAQ:QLI) -4%...

Gainers: Society Pass (NASDAQ:SOPA) +237%. Bluerock Residential Growth (NYSE:BRG) +71%. Can-Fite (NYSE:CANF) +59%. AeroClean (NASDAQ:AERC) +58%. Galera Therapeutics (NASDAQ:GRTX) +38%. Verso (NYSE:VRS) +35%. Roivant (NASDAQ:ROIV) +26%. Venus (NASDAQ:VERO) +25%. BioCardia (NASDAQ:BCDA) +1...